Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study
Tóm tắt
The aim of this study was to investigate if the flattening filter free (FFF) irradiation mode of a linear accelerator (linac) is advantageous as compared to the flat beam (FF) irradiation mode in intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for carcinoma of the hypopharynx / larynx. Four treatment plans were created for each of 10 patients for an Elekta Synergy linac with Agility collimating device, a dual arc VMAT and a nine field step and shoot IMRT each with and without flattening filter. Plan quality was compared considering target coverage and dose to the organs at risk. All plans were verified by a 2D–ionization-chamber-array and delivery times were compared. Peripheral point doses were determined as a measure of second cancer risk. The Wilcoxon test was used for statistical analysis with a significance level of 0.05. Plan quality was similar for all four treatment plans without statistically significant differences of clinical relevance. The clinical goals were met in all plans for the PTV-SIB (V95% > 95%), the spinal cord (D1ccm < 45 Gy) and the brain stem (D1ccm < 48 Gy). For the parotids, the goal of D50% < 30 Gy was met in 70% and 60% of the plans for the left and right parotid respectively, and the V95% of the SIB reached an average of 94%. Delivery times were similar for FF and FFF and significantly decreased by around 70% for VMAT as compared to IMRT. Peripheral doses were significantly reduced by 18% in FFF mode as compared to FF and by 26% for VMAT as compared to IMRT. Lowest peripheral doses were found for VMAT FFF, followed by VMAT FF. The FFF mode of a linear accelerator is advantageous for the treatment of hypopharynx/larynx carcinoma only with respect to reduction of second cancer induction in peripheral organs for the combination of Elekta Synergy linacs and Oncentra® External Beam v4.5 treatment planning system. This might be of interest in a therapy with curative intent.
Tài liệu tham khảo
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78. doi:10.1056/NEJMoa053422.
Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–205. doi:10.1016/j.ijrobp.2012.05.008.
Thariat J, Bolle S, Demizu Y, Marcy PY, Hu Y, Santini J, et al. New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? Anti-Cancer Drugs. 2011;22(7):596–606. doi:10.1097/CAD.0b013e328340fd2b.
Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, et al. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2012;82(2):539–47. doi:10.1016/j.ijrobp.2010.09.055.
Fogliata A, Bolsi A, Cozzi L, Bernier J. Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients. Radiother Oncol. 2003;69(3):267–75.
Franceschini D, Paiar F, Meattini I, Agresti B, Pasquetti EM, Greto D, et al. Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer. Laryngoscope. 2013;123(12):E97–103. doi:10.1002/lary.24257.
Franzese C, Fogliata A, Clerici E, Franceschini D, Villa E, D'Agostino G, et al. Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiat Oncol. 2015;10:224. doi:10.1186/s13014-015-0535-0.
Leclerc M, Maingon P, Hamoir M, Dalban C, Calais G, Nuyts S, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol. 2013;106(3):333–40. doi:10.1016/j.radonc.2013.03.002.
Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. Crit Rev Oncol Hematol. 2010;73(2):111–25. doi:10.1016/j.critrevonc.2009.03.003.
Chakraborty S, Ghoshal S, Patil V, Oinam A, Suresh S. Acute toxicities experienced during simultaneous integrated boost intensity-modulated radiotherapy in head and neck cancers--experience from a north Indian regional cancer centre. Clin Oncol (R Coll Radiol). 2009;21(9):676–86. doi:10.1016/j.clon.2009.07.017.
Georg D, Knoos T, McClean B. Current status and future perspective of flattening filter free photon beams. Med Phys. 2011;38(3):1280–93.
Kragl G, Baier F, Lutz S, Albrich D, Dalaryd M, Kroupa B, et al. Flattening filter free beams in SBRT and IMRT: dosimetric assessment of peripheral doses. Z Med Phys. 2011;21(2):91–101. doi:10.1016/j.zemedi.2010.07.003.
Lang S, Shrestha B, Graydon S, Cavelaars F, Linsenmeier C, Hrbacek J, et al. Clinical application of flattening filter free beams for extracranial stereotactic radiotherapy. Radiother Oncol. 2013;106(2):255–9. doi:10.1016/j.radonc.2012.12.012.
Lu JY, Lin Z, Lin PX, Huang BT. Optimizing the flattening filter free beam selection in RapidArc(R)-based stereotactic body radiotherapy for stage I lung cancer. Br J Radiol. 2015;88(1053):20140827. doi:10.1259/bjr.20140827.
Murray LJ, Thompson CM, Lilley J, Cosgrove V, Franks K, Sebag-Montefiore D, et al. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol. 2015;60(3):1237–57. doi:10.1088/0031-9155/60/3/1237.
Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013;107(3):414–8. doi:10.1016/j.radonc.2013.04.016.
Reggiori G, Mancosu P, Castiglioni S, Alongi F, Pellegrini C, Lobefalo F, et al. Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. Med Phys. 2012;39(2):1112–8. doi:10.1118/1.3679858.
Scorsetti M, Alongi F, Castiglioni S, Clivio A, Fogliata A, Lobefalo F, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;6:113. doi:10.1186/1748-717X-6-113.
Scorsetti M, Alongi F, Clerici E, Comito T, Fogliata A, Iftode C, et al. Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol. 2014;140(10):1795–800. doi:10.1007/s00432-014-1732-1.
Swamy ST, Radha CA, Arun G, Kathirvel M, Subramanian S. Planning and Dosimetric study of volumetric modulated arc based Hypofractionated stereotactic radiotherapy for acoustic Schwannoma - 6MV flattening filter free photon beam. Asian Pac J Cancer Prev. 2015;16(12):5019–24.
Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys. 2009;10(1):2880.
Zhuang M, Zhang T, Chen Z, Lin Z, Li D, Peng X, et al. Advanced nasopharyngeal carcinoma radiotherapy with volumetric modulated arcs and the potential role of flattening filter-free beams. Radiat Oncol. 2013;8:120. doi:10.1186/1748-717X-8-120.
Zhuang M, Zhang T, Chen Z, Lin Z, Li D, Peng X, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with conventional beams for nasopharyngeal carcinoma: a feasibility study. Chin J Cancer. 2013;32(7):397–402. doi:10.5732/cjc.012.10182.
Nicolini G, Ghosh-Laskar S, Shrivastava SK, Banerjee S, Chaudhary S, Agarwal JP, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;84(2):553–60. doi:10.1016/j.ijrobp.2011.12.041.
Spruijt KH, Dahele M, Cuijpers JP, Jeulink M, Rietveld D, Slotman BJ, et al. Flattening filter free vs flattened beams for breast irradiation. Int J Radiat Oncol Biol Phys. 2013;85(2):506–13. doi:10.1016/j.ijrobp.2012.03.040.
Subramaniam S, Thirumalaiswamy S, Srinivas C, Gandhi GA, Kathirvel M, Kumar KK, et al. Chest wall radiotherapy with volumetric modulated arcs and the potential role of flattening filter free photon beams. Strahlenther Onkol. 2012;188(6):484–90. doi:10.1007/s00066-012-0075-6.
Maier J, Knott B, Maerz M, Loeschel R, Koelbl O, Dobler B. Simultaneous integrated boost (SIB) radiation therapy of right sided breast cancer with and without flattening filter - a treatment planning study. Radiat Oncol. 2016;11(1):111. doi:10.1186/s13014-016-0687-6.
Bell K, Fleckenstein J, Nuesken F, Licht N, Rube C, Dzierma Y. mARC treatment of Hypopharynx carcinoma with flat and flattening-filter-free beam energies - a planning study. PLoS One. 2016;11(10):e0164616. doi:10.1371/journal.pone.0164616.
Kragl G, af Wetterstedt S, Knausl B, Lind M, McCavana P, Knoos T, et al. Dosimetric characteristics of 6 and 10MV unflattened photon beams. Radiother Oncol. 2009;93(1):141–6. doi:10.1016/j.radonc.2009.06.008.
Habl G, Potthoff K, Haefner MF, Abdollahi A, Hassel JC, Boller E, et al. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial. BMC Cancer. 2013;13:345. doi:10.1186/1471-2407-13-345.
Miyazaki M, Nishiyama K, Ueda Y, Ohira S, Tsujii K, Isono M, et al. Preliminary analysis of the sequential simultaneous integrated boost technique for intensity-modulated radiotherapy for head and neck cancers. J Radiat Res. 2016; doi:10.1093/jrr/rrw010.
Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76(5):1333–8. doi:10.1016/j.ijrobp.2009.04.011.
Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S58–63. doi:10.1016/j.ijrobp.2009.06.090.
Johnston M, Clifford S, Bromley R, Back M, Oliver L, Eade T. Volumetric-modulated arc therapy in head and neck radiotherapy: a planning comparison using simultaneous integrated boost for nasopharynx and oropharynx carcinoma. Clin Oncol (R Coll Radiol). 2011;23(8):503–11. doi:10.1016/j.clon.2011.02.002.
Paynter D, Weston SJ, Cosgrove VP, Evans JA, Thwaites DI. Beam characteristics of energy-matched flattening filter free beams. Med Phys. 2014;41(5):052103. doi:10.1118/1.4871615.
Dobler B, Khemissi A, Obermeier T, Hautmann MG, Katsilieri Z, Kolbl O. Re-irradiating spinal column metastases using IMRT and VMAT with and without flattening filter - a treatment planning study. Radiat Oncol. 2016;11(1):33. doi:10.1186/s13014-016-0603-0.
Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93(Suppl 3):219–22. doi:10.3171/jns.2000.93.supplement3.0219.
Low DA, Harms WB, Mutic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25(5):656–61.
Ezzell GA, Burmeister JW, Dogan N, LoSasso TJ, Mechalakos JG, Mihailidis D, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM task group 119. Med Phys. 2009;36(11):5359–73.
Ezzell GA, Galvin JM, Low D, Palta JR, Rosen I, Sharpe MB, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT subcommittee of the AAPM radiation therapy committee. Med Phys. 2003;30(8):2089–115.
Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168(1):1–64. doi:10.1667/RR0763.1.
Schneider U, Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys. 2008;47(2):253–63. doi:10.1007/s00411-007-0151-y.
Dobler B, Maier J, Knott B, Maerz M, Loeschel R, Koelbl O. Second cancer risk after simultaneous integrated boost radiation therapy of right sided breast cancer with and without flattening filter. Strahlenther Onkol. 2016;192(10):687–95. doi:10.1007/s00066-016-1025-5.